Figure 2.
Decitabine and tazemetostat activated transcription of HLA alleles on DLBCL cell lines. (A-G) SUDHL-6, DB, and SUDHL-4 cells were treated with indicated drugs (decitabine, 100 nM; tazemetostat, 1 μM; IFN-γ, 10 ng/mL). Graph of fold-change in transcript to untreated for each indicated gene (panels A, D, F) HLA-A, (panels B, E, G) HLA-B, and (panel C) HLA-C. ANOVA was performed using IFN-γ alone as control, followed by a post hoc Tukey’s test for individual experimental groups. Mean ± SD is shown for 3 technical replicates per 2 biological replicates. *P < .05; **P < .01; ****P < .0001.

Decitabine and tazemetostat activated transcription of HLA alleles on DLBCL cell lines. (A-G) SUDHL-6, DB, and SUDHL-4 cells were treated with indicated drugs (decitabine, 100 nM; tazemetostat, 1 μM; IFN-γ, 10 ng/mL). Graph of fold-change in transcript to untreated for each indicated gene (panels A, D, F) HLA-A, (panels B, E, G) HLA-B, and (panel C) HLA-C. ANOVA was performed using IFN-γ alone as control, followed by a post hoc Tukey’s test for individual experimental groups. Mean ± SD is shown for 3 technical replicates per 2 biological replicates. *P < .05; **P < .01; ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal